Astellas Pharma (JP:4503) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Astellas Pharma Inc. has announced the successful pricing of its 5th and 6th series JPY denominated unsecured bonds, aimed at repaying and redeeming short-term fundings. The bonds total JPY 100 billion, with the 5th series bond at JPY 80 billion with a 0.870% interest rate and a 5-year maturity, and the 6th series bond at JPY 20 billion with a 1.038% interest rate and a 7-year maturity. Both series are set to be publicly offered with no collateral guarantees but include a negative pledge clause, with Mizuho Securities and others as lead managers.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue